Potential global impact of sodium-glucose cotransporter-2 inhibitors in heart failure.
Cardiovascular death
Global
Heart failure
Hospitalization
Implementation
Sodium-glucose cotransporter-2 inhibitor
Journal
European journal of heart failure
ISSN: 1879-0844
Titre abrégé: Eur J Heart Fail
Pays: England
ID NLM: 100887595
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
31
03
2023
received:
11
02
2023
accepted:
05
04
2023
medline:
9
8
2023
pubmed:
18
4
2023
entrez:
17
4
2023
Statut:
ppublish
Résumé
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are effective across the spectrum of left ventricular ejection fraction (LVEF) in heart failure (HF); however, population-wide medication use in eligible patients remains suboptimal. We evaluated the potential implications of optimal global implementation of SGLT-2 inhibitors in HF. A decision analytical study was performed using the global prevalence of HF from the Global Burden of Disease 2017 report. Exclusion criteria were applied using the NHANES to ascertain an SGLT-2 inhibitor-eligible population, which was mapped onto global LVEF distributions from the REPORT-HF registry. The number needed to treat for 3 years for the composite of worsening HF events and cardiovascular deaths was calculated from estimated event rates in the DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, and DELIVER trials and projected onto the eligible population. An estimated 49 329 000 (95% confidence interval [CI] 43 882 000-54 929 000) HF patients would be eligible for SGLT-2 inhibitors across all LVEFs, including 25 651 000 (95% CI 22 818 000-28 563 000) with LVEF ≤40% and 23 678 000 (95% CI 21 063 000-26 366 000) with LVEF >40%. Optimal implementation of SGLT-2 inhibitors would be projected to prevent/postpone 4 512 011 (95% CI 4 013 686-5 024 232) to 5 986 943 (95% CI 5 325 721-6 666 604) total worsening HF events and cardiovascular deaths over 3 years in patients with LVEF <40%. An additional 2 102 606 (95% CI 1 870 394-2 341 301) to 2 557 224 (95% CI 2 274 804-2 847 528) total worsening HF events and cardiovascular deaths would be prevented/postponed in patients with LVEF >40%. Among all eligible HF patients, irrespective of LVEF, 7 069 235 (95% CI 6 288 490-7 871 760) to 8 089 549 (95% CI 7 196 115-9 007 905) total worsening HF events and cardiovascular deaths would be prevented/postponed over this period. Optimal implementation of SGLT-2 inhibitors globally in HF is projected to prevent/postpone approximately 7-8 million worsening HF events and cardiovascular deaths over 3 years.
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
999-1009Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 European Society of Cardiology.
Références
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995-2008.
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.; EMPEROR-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.
Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.; EMPEROR-Preserved Trial Investigators. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451-61.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, de Mets D, Hernandez AF, et al.; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089-98.
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire D, et al.; SOLOIST-WHF Trial Investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384:117-28.
Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28:568-74.
Talha KM, Butler J, Greene SJ, Aggarwal R, Anker SD, Claggett BL, et al. Population-level implications of sodium-glucose cotransporter-2 inhibitors for heart failure with preserved ejection fraction in the US. JAMA Cardiol. 2023;8:66-73.
Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A, et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. Eur J Prev Cardiol. 2021;28:1682-90.
Roth GA, Abate D, Abate KH, Abay SM, Abbafati C, Abbasi N, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736-88.
National Center for Health Statistics. Office of Analysis and Epidemiology. The Linkage of National Center for Health Statistics Survey Data to the National Death Index - 2015 Linked Mortality File (LMF): Methodology Overview and Analytic Considerations, November 2017. https://www.cdc.gov/nchs/data-linkage/mortality-methods.htm (last accessed 15 March 2023).
Filippatos G, Khan SS, Ambrosy AP, Cleland JGF, Collins SP, Lam CSP, et al. International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. Eur J Heart Fail. 2015;17:527-33.
Tromp J, Bamadhaj S, Cleland JGF, Angermann CE, Dahlstrom U, Ouwerkerk W, et al. Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. Lancet Glob Health. 2020;8:e411-22.
Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, et al. Health-related quality of life and mortality in heart failure: the Global Congestive Heart Failure study of 23 000 patients from 40 countries. Circulation. 2021;143:2129-42.
Mohebi R, Chen C, Ibrahim NE, McCarthy CP, Gaggin HK, Singer DE, et al. Cardiovascular disease projections in the United States based on the 2020 census estimates. J Am Coll Cardiol. 2022;80:565-78.
Dewan P, Rørth R, Jhund PS, Ferreira JP, Zannad F, Shen L, et al. Income inequality and outcomes in heart failure: a global between-country analysis. JACC Heart Fail. 2019;7:336-46.
Tromp J, Beusekamp JC, Ouwerkerk W, Meer P, Cleland JGF, Angermann CE, et al. Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the REPORT-HF registry. Eur J Heart Fail. 2022;24:645-52.
McKee M, Scarlatescu O, Wood D, Eiselé J-L, Perel P, Yusuf S. Access to essential medicines for circulatory diseases: a call to action. Glob Heart. 2019;14:399-400.
Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, et al.; PURE Study Investigators. Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. Lancet. 2016;387:61-9.
Chow CK, Nguyen TN, Marschner S, Diaz R, Rahman O, Avezum A, et al. Availability and affordability of medicines and cardiovascular outcomes in 21 high-income, middle-income and low-income countries. BMJ Glob Health. 2020;5:e002640.
Agarwal A, Husain MJ, Datta B, Kishore SP, Huffman MD. Access to heart failure medicines in low- and middle-income countries: an analysis of essential medicines lists, availability, price, and affordability. Circ Heart Fail. 2022;15:e008971.
Banerjee A, Khandelwal S, Nambiar L, Saxena M, Peck V, Moniruzzaman M, et al. Health system barriers and facilitators to medication adherence for the secondary prevention of cardiovascular disease: a systematic review. Open Heart. 2016;3:e000438.
Heneghan C, Blacklock C, Perera R, Davis R, Banerjee A, Gill P, et al. Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. BMJ Open. 2013;3:e003298.
Aggarwal R, Vaduganathan M, Chiu N, Bhatt DL. Out-of-pocket costs for SGLT-2 (sodium-glucose transport protein-2) inhibitors in the United States. Circ Heart Fail. 2022;15:287-9.
Johnson M, Nayak RK, Gilstrap L, Dusetzina SB. Estimation of out-of-pocket costs for guideline-directed medical therapy for heart failure under Medicare Part D and the Inflation Reduction Act. JAMA Cardiol. 2023;8:299-301.
American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S98-S110.
World Health Organization. Model List of Essential Medicines - 22nd list, 2021. https://list.essentialmeds.org (accessed 15 March 2023).
Ferreira JP, Zannad F, Pocock SJ, Anker SD, Butler J, Filippatos G, et al. Interplay of mineralocorticoid receptor antagonists and empagliflozin in heart failure: EMPEROR-Reduced. J Am Coll Cardiol. 2021;77:1397-407.
Dixit NM, Parikh NU, Ziaeian B, Jackson N, Fonarow GC. Cost-effectiveness of comprehensive quadruple therapy for heart failure with reduced ejection fraction. JACC Heart Fail. 2023;11:541-51.